CN113855791B - 抗微生物免疫调节 - Google Patents

抗微生物免疫调节 Download PDF

Info

Publication number
CN113855791B
CN113855791B CN202110547299.2A CN202110547299A CN113855791B CN 113855791 B CN113855791 B CN 113855791B CN 202110547299 A CN202110547299 A CN 202110547299A CN 113855791 B CN113855791 B CN 113855791B
Authority
CN
China
Prior art keywords
species
cells
infection
pathogen
macrophages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110547299.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113855791A (zh
Inventor
哈罗尔·戴维·贡
萨利姆·丹吉
戴维·W·穆林斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110547299.2A priority Critical patent/CN113855791B/zh
Publication of CN113855791A publication Critical patent/CN113855791A/zh
Application granted granted Critical
Publication of CN113855791B publication Critical patent/CN113855791B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202110547299.2A 2014-05-02 2015-05-01 抗微生物免疫调节 Active CN113855791B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110547299.2A CN113855791B (zh) 2014-05-02 2015-05-01 抗微生物免疫调节

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461988117P 2014-05-02 2014-05-02
US61/988,117 2014-05-02
CN202110547299.2A CN113855791B (zh) 2014-05-02 2015-05-01 抗微生物免疫调节
PCT/CA2015/050377 WO2015164979A1 (en) 2014-05-02 2015-05-01 Anti-microbial immunomodulation
CN201580030591.XA CN106456740B (zh) 2014-05-02 2015-05-01 抗微生物免疫调节

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580030591.XA Division CN106456740B (zh) 2014-05-02 2015-05-01 抗微生物免疫调节

Publications (2)

Publication Number Publication Date
CN113855791A CN113855791A (zh) 2021-12-31
CN113855791B true CN113855791B (zh) 2024-11-19

Family

ID=54357960

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110547299.2A Active CN113855791B (zh) 2014-05-02 2015-05-01 抗微生物免疫调节
CN201580030591.XA Active CN106456740B (zh) 2014-05-02 2015-05-01 抗微生物免疫调节

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580030591.XA Active CN106456740B (zh) 2014-05-02 2015-05-01 抗微生物免疫调节

Country Status (8)

Country Link
US (4) US10251946B2 (enExample)
EP (1) EP3137108A4 (enExample)
JP (1) JP6632607B2 (enExample)
CN (2) CN113855791B (enExample)
AU (2) AU2015252726B2 (enExample)
CA (2) CA3254723A1 (enExample)
RU (2) RU2724895C2 (enExample)
WO (1) WO2015164979A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980279B2 (en) * 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
CA3254723A1 (en) * 2014-05-02 2025-04-15 Qu Biologics Inc. ANTIMICROBIAL IMMUNOMODULATION
JP2019514939A (ja) 2016-04-26 2019-06-06 クー バイオロジックス インコーポレイテッドＱｕ Ｂｉｏｌｏｇｉｃｓ Ｉｎｃ． 標的組織における自然免疫応答の治療的誘発
WO2019134036A1 (en) 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
AU2019361036A1 (en) * 2018-10-17 2021-05-13 SciBac Inc. Live biotherapeutics to treat and prevent lung conditions
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
WO2021205077A1 (en) 2020-04-09 2021-10-14 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
WO2022067219A1 (en) * 2020-09-28 2022-03-31 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101954076A (zh) * 2009-04-27 2011-01-26 免疫制剂美国公司 自身免疫性肝炎的免疫疗法和预防
CN103140238A (zh) * 2010-07-26 2013-06-05 Qu生物制药公司 免疫原性抗炎组合物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928565A (en) 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
JPS5946493B2 (ja) 1978-03-31 1984-11-13 株式会社三和化学研究所 異種死菌体混合物を有効成分とする抗腫瘍剤
JPS568320A (en) 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS56108716A (en) 1980-01-30 1981-08-28 Sanwa Kagaku Kenkyusho:Kk Antiviral agent containing different kind dead cell mixture as effective component
JPS5839624A (ja) 1981-09-02 1983-03-08 Meiji Seika Kaisha Ltd 抗腫瘍剤
JPS6012071A (ja) 1983-06-30 1985-01-22 東レ株式会社 抗腫瘍作用を有する体液処理剤
US4880626A (en) 1985-01-18 1989-11-14 Mcmichael John Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome
US5292513A (en) 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
US5652332A (en) 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
GB9406301D0 (en) 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5869057A (en) 1995-06-07 1999-02-09 Rock; Edwin P. Recombinant vaccines to break self-tolerance
AU2429397A (en) 1996-03-29 1997-10-22 David S. Terman Polymerized staphylococcal protein a for treatment of diseases
US6348586B1 (en) 1996-07-25 2002-02-19 The Trustees Of Columbia University In The City Of New York Unique associated Kaposi's sarcoma virus sequences and uses thereof
US20020128240A1 (en) 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6028060A (en) 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
ES2368824T3 (es) 1998-03-27 2011-11-22 Oregon Health & Science University Vitamina d y sus análogos en el tratamiento de tumores y otros desórdenes hiperproliferativos.
AU2001233076A1 (en) 2000-02-01 2001-08-14 Michael A. O'donnell Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AUPQ761200A0 (en) * 2000-05-19 2000-06-15 Hunter Immunology Limited Compositions and methods for treatment of mucosal infections
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US7118740B1 (en) 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
FR2816844A1 (fr) 2000-11-17 2002-05-24 Pf Medicament Domaine periplasmique d'une proteine omp d'enterobacterie et son utilisation comme porteur et/ou adjuvant
GB2370770B (en) 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
FR2822071B1 (fr) 2001-03-15 2005-07-01 Pf Medicament Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
JP4206272B2 (ja) 2001-03-29 2009-01-07 サイナージィ ファーマスーティカルズ、インコーポレイテッド 組織炎症及び発癌を治療するためのグアニル酸シクラーゼ受容体アゴニスト
WO2003009859A1 (en) 2001-07-19 2003-02-06 Azuma, Ichiro Immunotherapy for humans
EP1281767A3 (en) 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
WO2003049751A1 (en) 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
DK1461054T3 (da) 2001-12-11 2010-08-16 Pasteur Institut Gram-positive bakteriepræparater til behandling af sygdomme omfattende en immundysregulering
WO2003063593A1 (en) 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
JP2005531289A (ja) 2002-02-15 2005-10-20 アゲルプ ファーマ ゲーエムベーハー Ｓ．ａｕｒｅｕｓエンテロトキシンＢ由来の免疫調節ペプチド
KR20050010040A (ko) 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
JP4618970B2 (ja) 2002-08-02 2011-01-26 マルホ株式会社 肛門圧低下外用剤
IL152127A0 (en) 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
AU2004206120B2 (en) 2003-01-21 2009-09-24 Yeda Research And Development Co. Ltd. COP 1 for treatment of inflammatory bowel diseases
AR043692A1 (es) 2003-02-06 2005-08-10 Novartis Ag 2-cianopirrolopirimidinas y sus usos farmaceuticos
CN101318019B (zh) 2003-04-23 2012-08-29 梅达雷克斯公司 含1型干扰素拮抗剂的组合物及其在制备治疗炎症性肠病的药物中的用途
EP1684803B1 (en) 2003-11-14 2010-07-07 UCL Business PLC Immune modulator comprising whole cell tsukamurella bacteria
US20050175630A1 (en) 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
US8501198B2 (en) * 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) * 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
PL1765391T3 (pl) 2004-06-07 2013-08-30 Qu Biologics Inc Kompozycje bakteryjne do leczenia nowotworów
US8029777B2 (en) 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
EP2040724B1 (en) 2006-05-18 2011-10-05 Biobalance Llc Biotherapeutic compositions comprising probiotic escherichia coli and metronidazole and uses thereof
MX2009002226A (es) 2006-08-28 2009-09-07 Omnio Healer Ab Candidatos contra infeccion.
NZ576590A (en) 2006-10-27 2012-08-31 Qu Biolog Inc Tissue targeted antigenic activation of the immune response to treat cancers
CA2571805C (en) 2006-10-27 2018-05-01 Harold David Gunn Tissue targeted antigenic activation of the immune response to cancers
EP2175880A1 (en) 2007-07-23 2010-04-21 Vaccine Research International PLC Inactivated staphylococcal whole-cell vaccine
EP2188366A1 (en) 2007-08-16 2010-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Human specific escherichia coli strains
HUP0700552A2 (en) 2007-08-27 2009-03-30 Janos Dr Feher Method and composition inhibiting inflammation
WO2010068413A1 (en) 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides
US8980279B2 (en) * 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
WO2015073801A1 (en) * 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
CA3254723A1 (en) * 2014-05-02 2025-04-15 Qu Biologics Inc. ANTIMICROBIAL IMMUNOMODULATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101954076A (zh) * 2009-04-27 2011-01-26 免疫制剂美国公司 自身免疫性肝炎的免疫疗法和预防
CN103140238A (zh) * 2010-07-26 2013-06-05 Qu生物制药公司 免疫原性抗炎组合物

Also Published As

Publication number Publication date
US20170087237A1 (en) 2017-03-30
AU2015252726B2 (en) 2020-12-24
RU2020120075A (ru) 2020-07-03
JP6632607B2 (ja) 2020-01-22
WO2015164979A1 (en) 2015-11-05
US11819543B2 (en) 2023-11-21
US10946083B2 (en) 2021-03-16
AU2020281030A1 (en) 2021-01-07
US20210138057A1 (en) 2021-05-13
AU2020281030B2 (en) 2024-08-08
RU2724895C2 (ru) 2020-06-26
US20240091330A1 (en) 2024-03-21
US20190247484A1 (en) 2019-08-15
CN106456740B (zh) 2021-06-08
JP2017514895A (ja) 2017-06-08
RU2016147048A (ru) 2018-06-05
CN113855791A (zh) 2021-12-31
CA3254723A1 (en) 2025-04-15
EP3137108A1 (en) 2017-03-08
US10251946B2 (en) 2019-04-09
EP3137108A4 (en) 2017-09-27
CN106456740A (zh) 2017-02-22
CA2947631A1 (en) 2015-11-05
AU2015252726A1 (en) 2016-11-10
RU2016147048A3 (enExample) 2019-02-22

Similar Documents

Publication Publication Date Title
CN113855791B (zh) 抗微生物免疫调节
JP6129378B2 (ja) 免疫原性抗炎症組成物
CA2611377C (en) Bacterial compositions for the treatment of cancer
CN110420226A (zh) 八宝丹在制备用于预防或治疗与il-6炎症因子风暴相关的疾病的药物中的用途
CN105816863A (zh) 免疫原性抗炎组合物
PT1272216E (pt) Vacina compreendendo lactobacilos para o tratamento da inflamação da próstata e de hiperplasias benignas da próstata
KR20240163211A (ko) 건락성 림프절염 감염 염소로부터 분리된 신규 코리네박테리움 슈도투베르쿨로시스 균주 및 이를 포함하는 건락성 림프절염 예방용 백신 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant